Sign In
Buy ALT
$2.84
-0.140 (-4.70%)
At Close: Jul 31, 2026
Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly
02:06pm, Friday, 23'rd Jan 2026
Shares of Altimmune ( NASDAQ:ALT ) surged 35.4% over the past week, coinciding with a dramatic shift in retail investor sentiment on Reddit.
ALT5 Sigma Corporation Launches ALT5 AI to Power the Next Era of Enterprise AI—Where Crypto, Compliance and AI Payment Rails Converge
08:00am, Wednesday, 21'st Jan 2026
LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (NASDAQ: ALTS) (FRA:5AR1) (“ALT5” or the “Company”), a fintech company that maintains a strategic $WLFI digital asset treasury and provides b
ALT5 Sigma Corporation Restores Compliance with Nasdaq Periodic Filing Requirements
08:00am, Wednesday, 14'th Jan 2026
LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (the “Company” or “ALT5”) (NASDAQ: ALTS)(FRA: 5AR1) today announced that it received a notification letter (the “Letter”) from The Nasdaq
ALT5 Sigma Corporation Reports Q3 2025 Financial Results and Significant Milestones
08:23am, Monday, 12'th Jan 2026
LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (NASDAQ: ALTS) (the “Company”), a fintech company that maintains a strategic $WLFI digital asset treasury and provides blockchain-powered payment
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH
12:55pm, Tuesday, 06'th Jan 2026
Altimmune shares rally 16.52% after the FDA grants Breakthrough Therapy status to pemvidutide for MASH.
ALT5 Sigma Expects to File its Quarterly Report on Form 10-Q for the Third Quarter 2025 in the Coming Days
08:00am, Monday, 05'th Jan 2026
LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (the “Company” or “ALT5”) (NASDAQ: ALTS)(FRA: 5AR1), a fintech company operating institutional-grade global payments, trading, and settlement
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
07:30am, Monday, 05'th Jan 2026
Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with U.S. FDA Alignment on Phase 3 registrational trial parameters confirmed fol
ALT5 Sigma Congratulates Strategic Partner World Liberty Financial on USD1 Stablecoin Surpassing $3 Billion Market Capitalization
08:30am, Tuesday, 30'th Dec 2025
LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (the “Company” or “ALT5”) (NASDAQ: ALTS)(FRA: 5AR1), a fintech company operating institutional-grade global payments, trading, and settlement
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
11:15am, Monday, 29'th Dec 2025
Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.
San Diego, California--(Newsfile Corp. - December 24, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving ALT5 Sigm
Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen
07:42pm, Tuesday, 23'rd Dec 2025
Altimmune delivered strong 48-week Phase IIb data for pemvidutide in MASH, supporting progression to Phase III. Pemvidutide showed durable, dose-dependent improvements in non-invasive fibrosis markers
Altimmune (NASDAQ:ALT) Director Jerome Benedict Durso Acquires 12,500 Shares of Stock
05:01am, Tuesday, 23'rd Dec 2025
Altimmune, Inc. (NASDAQ: ALT - Get Free Report) Director Jerome Benedict Durso acquired 12,500 shares of the firm's stock in a transaction on Monday, December 22nd. The stock was bought at an average
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of “Moderate Buy” by Analysts
01:14am, Tuesday, 23'rd Dec 2025
Shares of Altimmune, Inc. (NASDAQ: ALT - Get Free Report) have been given an average recommendation of "Moderate Buy" by the ten ratings firms that are currently covering the firm, Marketbeat reports.
Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks
12:57pm, Friday, 19'th Dec 2025
Altimmune Inc. (NASDAQ: ALT) on Friday shared topline results from the IMPACT Phase 2b trial of pemvidutide.
Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript
11:37am, Friday, 19'th Dec 2025
Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript
